ABSTRACT
The SARS-CoV-2 pandemic revealed the fragility of global supply chains, resulting in shortages of essential clinical supplies for the detection and treatment of COVID-19, including nasopharyngeal swabs (NP) commonly used to collect clinical samples for respiratory disease diagnostics. Groups around the world led a response to find alternatives to these shortages. Here, we describe the development of a single-component nasopharyngeal swab (GrooveSwab) composed of medical grade polypropylene that can be mass manufactured using conventional injection molding. The design inspired by cat tongue papillae consists of a non-absorbent stacked ring structure that allows for efficient and comfortable collection of viscous mucus samples and faster release into collection medium compared to traditional absorbent swabs. GroveSwabs were evaluated in 2 clinical studies in the US and Peru and demonstrated 90% or better concordance with commercial swabs. The simplified NP swab offers a reliable, lower cost, and more manufacturable alternative to absorbent swabs to avoid future shortages.
Competing Interest Statement
MRM, DEI, and RN are listed as inventors on licensed patents related to this work. RN is a member of the fiduciary board and holds equity in Rhinostics Inc., a licensee of the patents.
Clinical Trial
The study was not registered in clinicaltrials.gov as it did not meet the definition of an Applicable Clinical Trial as it was not an interventional study according to https://prsinfo.clinicaltrials.gov/ACT_Checklist.pdf The retrospective analysis of the data was determined to be non-human subjects research by the TGen Office of Research Compliance & Quality Management, which is the ethics and research protections office for the TGen.
Funding Statement
This work was supported with funding from the Wyss Institute for Biologically Inspired Engineering at Harvard University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
SUNY Downstate IRB protocol number 1611734-2 was used for the clinical trial. The TGen North study comparing the prototype GrooveSwab against a Copan FLOQSwab (Copan Diagnostics, Murietta, CA, USA) involved the retrospective analysis of anonymous human data that had originally been generated in validation testing as part of a clinical laboratory quality assurance program. The original samples were collected from healthy volunteers who were participating in a workplace surveillance testing program. The retrospective analysis of the data was determined to be non-human subjects research by the TGen Office of Research Compliance & Quality Management.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw data not included in the manuscript are available from the corresponding author upon reasonable request.
